These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33680018)

  • 1. Inhibition of Cyclin-dependent Kinase (CDK) Decreased Survival of NB4 Leukemic Cells: Proposing a p53-Independent Sensitivity of Leukemic Cells to Multi-CDKs Inhibitor AT7519.
    Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Shanaki M; Yousefi AM; Anjam Najmedini A; Bashash D
    Iran J Pharm Res; 2020; 19(3):144-155. PubMed ID: 33680018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
    Zabihi M; Safaroghli-Azar A; Gharehbaghian A; Allahbakhshian Farsani M; Bashash D
    Iran J Pharm Res; 2019; 18(Suppl1):119-131. PubMed ID: 32802093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status.
    Bashash D; Sayyadi M; Safaroghli-Azar A; Sheikh-Zeineddini N; Riyahi N; Momeny M
    Int J Biochem Cell Biol; 2019 Mar; 108():7-16. PubMed ID: 30639430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
    Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
    Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
    Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
    Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
    Wei X; Nian J; Zheng J; He Y; Zeng M
    Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Esmaeili S; Yousefi AM; Delshad M; Bashash D
    Mol Genet Genomic Med; 2023 Mar; 11(3):e2106. PubMed ID: 36398521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Korean red ginseng extract induces proliferation to differentiation transition of human acute promyelocytic leukemia cells via MYC-SKP2-CDKN1B axis.
    Jo S; Lee H; Kim S; Lee CH; Chung H
    J Ethnopharmacol; 2013 Nov; 150(2):700-7. PubMed ID: 24095829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
    Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
    Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest.
    Zhao W; Zhang L; Zhang Y; Jiang Z; Lu H; Xie Y; Han W; Zhao W; He J; Shi Z; Yang H; Chen J; Chen S; Li Z; Mao J; Zhou L; Gao X; Li W; Tan G; Zhang B; Wang Z
    Cell Death Dis; 2023 Jan; 14(1):11. PubMed ID: 36624090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Hassani S; Khaleghian A; Ahmadian S; Alizadeh S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Ann Hematol; 2018 Jan; 97(1):83-93. PubMed ID: 29159499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF-κB-dependent Mechanism of Action of c-Myc Inhibitor 10058-F4: Highlighting a Promising Effect of c-Myc Inhibition in Leukemia Cells, Irrespective of p53 Status.
    Sayyadi M; Safaroghli-Azar A; Safa M; Abolghasemi H; Momeny M; Bashash D
    Iran J Pharm Res; 2020; 19(1):153-165. PubMed ID: 32922477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
    Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
    Oncotarget; 2018 Jan; 9(4):5216-5232. PubMed ID: 29435174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis.
    Safa M; Mousavizadeh K; Noori S; Pourfathollah A; Zand H
    Eur J Pharmacol; 2014 Aug; 736():115-23. PubMed ID: 24815320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
    Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
    Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.
    Pourbagheri-Sigaroodi A; Bashash D; Safaroghli-Azar A; Farshi-Paraasghari M; Momeny M; Mansoor FN; Ghaffari SH
    Eur J Pharmacol; 2019 Mar; 846():49-62. PubMed ID: 30658112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis.
    Sayyadi M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Abolghasemi H; Anoushirvani AA; Bashash D
    Arch Med Res; 2020 Oct; 51(7):636-644. PubMed ID: 32553459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1.
    Hermeking H; Funk JO; Reichert M; Ellwart JW; Eick D
    Oncogene; 1995 Oct; 11(7):1409-15. PubMed ID: 7478565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519.
    Karaś K; Karwaciak I; Chałaśkiewicz K; Sałkowska A; Pastwińska J; Bachorz RA; Ratajewski M
    Biomed Pharmacother; 2023 Aug; 164():115002. PubMed ID: 37311277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.